Impact of resection margin status on survival in advanced N stage pancreatic cancer – a multi-institutional analysis
-
Published:2021-03-13
Issue:5
Volume:406
Page:1481-1489
-
ISSN:1435-2443
-
Container-title:Langenbeck's Archives of Surgery
-
language:en
-
Short-container-title:Langenbecks Arch Surg
Author:
Teske Christian,Stimpel Richard,Distler Marius,Merkel Susanne,Grützmann Robert,Bolm Louisa,Wellner Ulrich,Keck Tobias,Aust Daniela E.,Weitz Jürgen,Welsch Thilo
Abstract
Abstract
Background
The present study aimed to examine the impact of microscopically tumour-infiltrated resection margins (R1) in pancreatic ductal adenocarcinoma (PDAC) patients with advanced lymphonodular metastasis (pN1–pN2) on overall survival (OS).
Methods
This retrospective, multi-institutional analysis included patients undergoing surgical resection for PDAC at three tertiary university centres between 2005 and 2018. Subcohorts of patients with lymph node status pN0–N2 were stratified according to the histopathological resection status using Kaplan-Meier survival analysis.
Results
The OS of the entire cohort (n = 620) correlated inversely with the pN status (26 [pN0], 18 [pN1], 11.8 [pN2] months, P < 0.001) and R status (21.7 [R0], 12.5 [R1] months, P < 0.001). However, there was no statistically significant OS difference between R0 versus R1 in cases with advanced lymphonodular metastases: 19.6 months (95% CI: 17.4–20.9) versus 13.6 months (95% CI: 10.7–18.0) for pN1 stage and 13.7 months (95% CI: 10.7–18.9) versus 10.1 months (95% CI: 7.9–19.1) for pN2, respectively. Accordingly, N stage–dependent Cox regression analysis revealed that R status was a prognostic factor in pN0 cases only. Furthermore, there was no significant survival disadvantage for patients with R0 resection but circumferential resection margin invasion (≤ 1 mm; CRM+; 10.7 months) versus CRM-negative (13.7 months) cases in pN2 stages (P = 0.5).
Conclusions
An R1 resection is not associated with worse OS in pN2 cases. If there is evidence of advanced lymph node metastasis and a re-resection due to an R1 situation (e.g. at venous or arterial vessels) may substantially increase the perioperative risk, margin clearance in order to reach local control might be avoided with respect to the OS.
Funder
Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O’Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406. https://doi.org/10.1056/NEJMoa1809775 2. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024. https://doi.org/10.1016/S0140-6736(16)32409-6 3. Nitschke P, Volk A, Welsch T, Hackl J, Reissfelder C, Rahbari M, Distler M, Saeger HD, Weitz J, Rahbari NN (2017) Impact of intraoperative re-resection to achieve R0 status on survival in patients with pancreatic cancer: a single-center experience with 483 patients. Ann Surg 265:1219–1225. https://doi.org/10.1097/SLA.0000000000001808 4. Tarantino I, Warschkow R, Hackert T, Schmied BM, Büchler MW, Strobel O, Ulrich A (2017) Staging of pancreatic cancer based on the number of positive lymph nodes. BJS (British Journal of Surgery) 104:608–618. https://doi.org/10.1002/bjs.10472 5. van Roessel S, Kasumova GG, Verheij J, et al. (2018) International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system in patients with resected pancreatic cancer. JAMA Surg 153:e183617. https://doi.org/10.1001/jamasurg.2018.3617
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|